I agree that we don’t really know what ADXS has planned, but that is not unusual for a biotech. Lombardo has confirmed repeatedly that he is looking to monetize, and that is all we are going to get from him until we get clued in. However, I disagree with the premise that management and the board are apathetic or that they are just looking to “milk” the company for their own benefit.